Notably, the combination of Acalabrutinib and Osimertinib exhibited significant tumor growth inhibition in vivo, indicating that Acalabrutinib could potentiate mice-bearing EGFR TKI-resistant tumors to Osimertinib treatment (Fig. 7). The gene discussed is EGFR; the disease is neoplasm.